The preliminary VS-7375 data supports a potential best-in-class profile. With FDA meeting and Phase 3 initiation milestones set for 2H 2026 and 1H 2027, the next catalyst is the mid-2026 update from TARGET-D 101. Beware of early-stage hype.
Price Chart
Executive Summary
Verastem announced positive preliminary Phase 1/2 data for its KRAS G12D (ON/OFF) inhibitor VS-7375 across pancreatic, colorectal, and lung cancers at 900 mg QD, showing 93% CA19-9 reduction in heavily pre-treated mPDAC patients and a favorable safety profile. The company also disclosed an intent to enter a preclinical collaboration with Erasca to evaluate VS-7375 in combination with a pan-RAS molecular glue, ERAS-0015.
Key Facts
- 93% (13/14) of heavily pre-treated mPDAC patients at 900 mg QD achieved >50% CA19-9 reduction; all remain on treatment
- Confirmed partial responses observed at 900 mg QD monotherapy in mPDAC and 600 mg QD in NSCLC
- VS-7375 900 mg + cetuximab DLT-cleared in May 2026 for mCRC; enrollment ongoing in TARGET-D 203 registration-directed trial
- Safety profile favorable: primarily low-grade GI AEs that attenuate after cycle 1; no clinically meaningful liver or hematologic toxicity
- Company plans to complete enrollment across all three TARGET-D Phase 2 trials by end of 2026 and enroll first Phase 3 patient by 1H 2027
- Erasca collaboration announced: preclinical combo of VS-7375 + ERAS-0015 (pan-RAS molecular glue) to be explored
Financial Impact
No revenue or earnings disclosed; the filing is a clinical data update. Therapeutic franchise opportunity if approved, with a combined U.S. TAM of ~61K patients annually in PDAC, CRC, and NSCLC.
Risk Factors
- Early-stage data (dose escalation/expansion) may not replicate in larger pivotal trials
- Competition from other KRAS G12D inhibitors (e.g., zoldonrasib, daraxonrasib) could limit market share
- Company history of losing capital on prior positive reads — stock may sell off on the news
- No financial data filed; cash runway and financing needs are not disclosed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-076809 |
| Document: tm2618546d1_8k.htm | 0001104659-26-076809 |
| Document: 0001104659-26-076809-index-headers.html | 0001104659-26-076809 |
| Document: 0001104659-26-076809-index.html | 0001104659-26-076809 |
| Document: 0001104659-26-076809.txt | 0001104659-26-076809 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $9.23 | awaiting T+60 | — | $10.06 (−8.99%) |
Oct 14, 2026 12d ago | 424B5 | $9.23 | awaiting T+60 | — | $10.06 (−8.99%) |
Oct 14, 2026 12d ago | 424B5 | $9.23 | awaiting T+60 | — | $10.06 (−8.99%) |
Oct 14, 2026 13d ago | 8-K | $7.71 | awaiting T+60 | — | $10.06 (+30.48%) |
Oct 2, 2026 24d ago | Insider Cluster | $8.00 | awaiting T+60 | — | $10.06 (−25.75%) |
Jun 23, 2026 17w ago | 8-K | $3.85 $7.55 | ▲ +96.10% | ▲ +93.27% | $10.06 (+161.30%) |
Jun 17, 2026 18w ago | 8-K | $4.17 $7.32 | ▲ +75.54% | ▲ +72.39% | $10.06 (+141.25%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.10 $8.08 | ▲ +97.07% | ▲ +93.81% | $10.06 (+145.37%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.94 $8.20 | ▲ +108.12% | ▲ +103.73% | $10.06 (+155.33%) |
May 27, 2026 21w ago | 3 | $4.29 $6.89 | ▲ +60.61% | ▲ +58.87% | $10.06 (+134.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers